Sevelamer does not decrease lipopolysaccharide or soluble cd14 levels but decreases soluble tissue factor, low-density lipoprotein (ldl) cholesterol, and oxidized ldl cholesterol levels in individuals with untreated hiv infection

Journal of Infectious Diseases

Volumn 210, Issue 10, 2014, Pages 1549-1554

  Sandler, Netanya G ^a   Zhang, Xinyan ^b   Bosch, Ronald J ^c   Funderburg, Nicholas T ^d   Choi, Andrew I ^m   Robinson, Janet K ^f   Fine, Derek M ^h   Coombs, Robert W ^g   Jacobson, Jeffrey M ^l   Landay, Alan L ^k   Douek, Daniel C ⁱ   Tressler, Randall ^j   Read, Sarah W ^e   Wilson, Cara C ^g   Deeks, Steven G ^a   Lederman, Michael M ^f   Gandhi, Rajesh T ^e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g Department of Medicine ^*  (United States)

^h University of California   (United States)

ⁱ SAN FRANCISCO GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

HIV; LDL; LPS; microbial translocation; oxLDL.; sCD14; sevelamer; soluble tissue factor

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; D DIMER; FETUIN A; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; SEVELAMER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; POLYAMINE; THROMBOPLASTIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; NONHUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; BACTERIAL TRANSLOCATION; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; HIV INFECTIONS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIGENS, CD14; BACTERIAL TRANSLOCATION; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; POLYAMINES; THROMBOPLASTIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84912144937     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu305     Document Type: Article

References (15)

1. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51-83.
2. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-66.
3. Sun PP, Perianayagam MC, Jaber BL. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr 2009; 19:432-8.
4. Stinghen AE, Goncalves SM, Bucharles S, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010; 29:352-6.
5. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6:2272-9.
6. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820-5.
7. Iimori S, Mori Y, Akita W, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 2012; 16:930-7.
8. Owens AP, Mackman N. Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque. Thromb Res 2012; 129(suppl 2):S30-3.
9. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83:1010-6.
10. Manner IW, Troseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich) 2013; 15:101-6.
11. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
12. Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150:301-13.
13. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-12.
14. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-608.
15. Dichtl W, Stiko A, Eriksson P, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:3025-32